MHRA reissues LABA advice

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a reminder to prescribers on the use of long-acting ß2 agonists.

LABAs are indicated for long-term use and not to relieve acute asthma symptoms.
LABAs are indicated for long-term use and not to relieve acute asthma symptoms.

The advice is consistent with the guidelines issued by the British Thoracic Society and Scottish Intercollegiate Guidelines Network. It reminds prescribers:

  • To prescribe long-acting β2 agonists (LABAs) only with inhaled corticosteroids (ICS) and when ICS alone fail to control asthma symptoms.
  • Not to initiate LABA treatment in patients with rapidly deteriorating asthma.
  • To use the lowest effective dose, review treatment regularly, and discontinue if there is no benefit.
  • To consider stepping-down when good long-term asthma control is achieved.
  • Not to prescribe LABA for exercise-induced asthma without regular ICS (a short-acting β2-agonist should be used instead).
  • To prescribe combination inhalers when appropriate.

See the MIMS summary of BTS/SIGN asthma guidelines for more information.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Regular emollient use does not prevent eczema in children

Regular emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...